CompanyHealthHardware
Crossbow Therapeutics, Inc.
Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company building a new class of cancer immunotherapies. Its T-Bolt platform engineers TCR-mimetic antibodies - T-cell engagers that recognize tiny peptide fragments displayed on a cancer cell's surface (peptide-HLA complexes), opening up intracellular proteins that conventional antibodies cannot reach. The lead program, CBX-250, is a first-in-class T-cell engager in a Phase 1 trial for relapsed or refractory myeloid malignancies. Backed by more than $157M in venture funding, Crossbow aims to expand the universe of targetable cancer antigens.
2021Founded
CambridgeHQ
$77 millionSeries B
biotechnologycancer-immunotherapytcr-mimetic-antibodiest-cell-engagersoncologyimmuno-oncology
